Cargando…
The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes
Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of multiple myeloma that also displays unique regulatory activities on immune cells. The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme exerting potent immunoregulatory effects when ex...
Autores principales: | Mondanelli, Giada, Albini, Elisa, Pallotta, Maria T., Volpi, Claudia, Chatenoud, Lucienne, Kuhn, Chantal, Fallarino, Francesca, Matino, Davide, Belladonna, Maria L., Bianchi, Roberta, Vacca, Carmine, Bicciato, Silvio, Boon, Louis, Ricci, Giovanni, Grohmann, Ursula, Puccetti, Paolo, Orabona, Ciriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5390013/ https://www.ncbi.nlm.nih.gov/pubmed/28450863 http://dx.doi.org/10.3389/fimmu.2017.00428 |
Ejemplares similares
-
Distinct roles of immunoreceptor tyrosine‐based motifs in immunosuppressive indoleamine 2,3‐dioxygenase 1
por: Albini, Elisa, et al.
Publicado: (2016) -
Proteasomal Degradation of Indoleamine 2,3-Dioxygenase in CD8(+) Dendritic Cells is Mediated by Suppressor of Cytokine Signaling 3 (SOCS3)
por: Pallotta, Maria T., et al.
Publicado: (2010) -
Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes
por: Pallotta, Maria Teresa, et al.
Publicado: (2014) -
Stem cells from human amniotic fluid exert immunoregulatory function via secreted indoleamine 2,3-dioxygenase1
por: Romani, Rita, et al.
Publicado: (2015) -
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
por: Coletti, Alice, et al.
Publicado: (2017)